Myriad Genetics, Inc., a molecular diagnostics company, develops and markets predictive, personalized, and prognostic medicine tests in the United States and internationally. The company is headquartered in Salt Lake City, Utah.
| Revenue (TTM) | $557.00M |
| Gross Profit (TTM) | $379.10M |
| EBITDA | $-111.90M |
| Operating Margin | -21.40% |
| Return on Equity | -23.50% |
| Return on Assets | -7.65% |
| Revenue/Share (TTM) | $7.45 |
| Book Value | $3.57 |
| Price-to-Book | 1.53 |
| Price-to-Sales (TTM) | 0.90 |
| EV/Revenue | 0.726 |
| EV/EBITDA | -23.47 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -20.80% |
| Shares Outstanding | $94.45M |
| Float | $85.99M |
| % Insiders | 3.76% |
| % Institutions | 95.85% |
Volatility is currently contracting
SALT LAKE CITY, July 23, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its second quarter 2026 earnings conference call at 4:30 pm ET on Thursday, July 30, 2026. The company's quarterly earnings will be released the same day after the market closes.
Myriad Genetics Launches FirstGene® Multiple Prenatal Screen: The only lab test to run four prenatal genetic screens simultaneously as early as eight weeks
Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid advances in personalized medicine and synthetic biology continue to transform the industry.
Myriad Genetics, Inc. MYGN is well-placed for growth in the coming quarters due to its steady rollout of new testing panels and product enhancements. The company is also progressing in its Cancer Care Continuum strategy, supported by rising demand in hereditary cancer and a 2026 launch calendar.
New published data shows Prolaris Biopsy Test adds significant prognostic information beyond conventional clinical risk categories for prostate cancer.
Myriad (MYGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Publication of MONITOR-Breast study marks latest milestone for clinical validity of Precise MRD Publication of MONITOR-Breast study marks latest milestone for clinical validity of Precise MRD
MYGN is gearing up with oncology testing and steady product launches, backed by sound solvency, though foreign-exchange swings could weigh on results.
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock?
Genomics and synthetic biology are reshaping healthcare, with growing demand for precision medicine spotlighting stocks like PACB, MYGN and TWST.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MYGN and any ticker you trade — then tracks every position and per-strategy win rate.
